Sunitinib Malate Size:Solid 2 mg It was also used in

It was also used in animal models to treat FOP and ectopic ossification

also known as PSI-6206 and RO-2433

Bcl-xL and Mcl-1 cooperate to protect cancer cells against apoptosis and their concomitant inhibition leads to massive apoptosis even in the absence of chemotherapy

72(12):3060-8

13)/t9-/m1/s1

Sunitinib Malate Size:Solid 2 mg It was also used inSunitinib, also known as SU11248, is the orally bioavailable malate salt of an indolinone based tyrosine kinase inhibitor with potential antineoplastic activity. Sunitinib was approved by the FDA for the treatment of renal cell carcinoma (RCC) and imatinib resistant gastrointestinal stromal tumor (GIST) on January 26, 2006. Sunitinib blocks the tyrosine kinase activities of vascular endothelial growth factor receptor 2 (VEGFR2), platelet derived